Studies Show Certain Protein Could Benefit Multiple Sclerosis
There was marked improvement
The IL-12p35 subunit treatment was delivered every other day for 12 days, and mice were monitored for b-cell count and inflammation to the brain and spinal cord, regions most commonly affected by multiple sclerosis. After the 12-day mark, the mice showed marked improvement in symptoms, and a greater proliferation of b-cells that counteracted inflammation, just like the mice in the uveitis study.